Kevin Tracey, M.D., president and CEO of the Feinstein Institute for Medical Research, was profiled in a New York Times article on May 23 on his ground-breaking research making the connection between the nervous and immune systems.
The Feinstein Institute has been a strong supporter of PAN and most recently sponsored our telehealth event in Washington, DC.
In the 1990s, Tracey, a neurosurgeon and researcher, made a link between the vagus nerve and the immune system in rats. According to the article, Tracey’s work “seemed to indicate that electricity delivered to the vagus nerve in just the right intensity and at precise intervals could reproduce a drug’s therapeutic — in this case, anti-inflammatory — reaction.”
This discovery has spurred recent development of bioelectronics and Tracey said he sees bioelectronics as eventually replacing many drug therapies. In fact, SetPoint Medical has begun the world’s first clinical trial to treat rheumatoid-arthritis patients with an implantable nerve stimulator based on Tracey’s discoveries.
In addition to explaining the bioelectronics implant in more detail, the New York Times article also includes information about the growing concern that these devices, particularly when wireless, could be hacked.
To read the full article, click here.